Results 71 to 80 of about 40,497 (266)

Evaluation of illicit drug contaminants in seized cannabis in Arizona and California, 2023–2024

Journal of Forensic Sciences, EarlyView.
Abstract Despite public health concerns, fentanyl, cocaine, and other illicit drug contaminants remain largely understudied in unregulated cannabis. Here, we developed an analytical method to quantify a panel of common illicit drugs in cannabis and tested the law enforcement seizures in Arizona and California in evaluation of the illicit drug ...
Beckner Andersano, Thomas M. Cahill, Michael Grommes, Maxwell C. K. Leung   +3 more
wiley   +1 more source

Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders

Frontiers in Psychology, 2019
Accumulated evidence indicates that cannabidiol (CBD), a nonpsychotomimetic and nonaddictive main component of the Cannabis sativa plant, reverses anxiety-like behavior.
Nobuo Masataka
doaj   +1 more source

Prevalence of novel psychoactive substances in selected clinical urine specimens submitted for drug monitoring

Journal of Forensic Sciences, EarlyView.
Abstract Novel psychoactive substances (NPS) are compounds emerging as alternatives to more established drugs of abuse. They are constantly changing and being modified, which makes their detection difficult. The study objective was to determine the prevalence of NPS in selected clinical specimens. Deidentified urine specimen remnants were analyzed that
Jillian R. Neifeld, Theresa M. Meli, Sarah H. Bartock   +2 more
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Consumer perspectives of accessing medicinal cannabis treatment from cannabis clinics versus generalist health settings in Australia

Journal of Cannabis Research
Objectives To examine consumer perspectives regarding medicinal cannabis treatment provided to patients attending generalist health settings (GHS) compared to those attending medicinal cannabis clinics (MCC).
Nicholas Lintzeris, Jonathon C Arnold, Iain S McGregor, Llewellyn Mills   +3 more
doaj   +1 more source

Cannabinoids Block Fat-induced Incretin Release via CB1-dependent and CB1-independent Pathways in Intestinal Epithelium

Gastro Hep Advances
Background and Aims: Glucose homeostasis is regulated by a dynamic interplay between hormones along the gastro-insular axis. For example, enteroendocrine L- and K- cells that line the intestine produce the incretins glucagon-like peptide-1 (GLP1) and ...
Pedro Antonio Perez, Mark Benjamin Wiley, Alexandros Makriyannis, Nicholas Vincent DiPatrizio   +3 more
doaj   +1 more source

Impact of cannabis, cannabinoids and endocannabinoids in the lungs

Frontiers in Pharmacology, 2016
Since the identification of cannabinoid receptors in the 1990s, a research field has been dedicated to exploring the role of the cannabinoid system in immunity and the inflammatory response in human tissues and animal models.
Caroline Turcotte, Marie-Renée Blanchet, Michel Laviolette, Nicolas Flamand   +3 more
doaj   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

3D-QSAR/CoMFA-Based Structure-Affinity/Selectivity Relationships of Aminoalkylindoles in the Cannabinoid CB1 and CB2 Receptors

Molecules, 2014
A 3D-QSAR (CoMFA) study was performed in an extensive series of aminoalkylindoles derivatives with affinity for the cannabinoid receptors CB1 and CB2.
Jaime Mella-Raipán, Santiago Hernández-Pino, César Morales-Verdejo, David Pessoa-Mahana   +3 more
doaj   +1 more source